Aminoglycosides Linked to Sensorineural Hearing Loss in Children With Cystic Fibrosis
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Aminoglycosides Linked to Sensorineural Hearing Loss in Children With Cystic Fibrosis

ALEXANDRIA, Va -- July 1, 2009 -- An otherwise effective treatment for cystic fibrosis places paediatric patients at a high risk of sensorineural hearing loss, according to a study published in the July edition of Otolaryngology-Head and Neck Surgery.

Children with cystic fibrosis who receive systemic or intranasal aminoglycosides have a higher risk of sensorineural hearing loss.

Alan G. Cheng, MD, Children’s Hospital of Boston, Boston, Massachusetts, and colleagues reviewed the medical records of children with cystic fibrosis (CF) that were treated at the Children’s Hospital of Boston over a 13 year period.

They found that 7 of 50 (14%) patients with cystic fibrosis suffered from sensorineural hearing loss.

Of that group, 43% of those that had received aminoglycosides intravenously had received more than 10 courses of the treatment; patients who were treated more than 5 times with nasal irrigation of aminoglycosides were also at risk of sensorineural hearing loss.

Because patients with cystic fibrosis are prone to suffer from infections of the pulmonary and sinonasal systems, aminoglycosides are commonly administered.

The treatment is considered so effective that it outweighs the well-known side-effects, which include hair cell loss, and thus hearing loss.

The authors contend that patients with cystic fibrosis should have routine hearing evaluations that specifically target the detection of sensorineural hearing loss, especially when repeated courses of systemic or intranasal aminoglycosides have be used in treatment.

They also noted that further investigation through a prospective study is warranted in order to replicate these results.

SOURCE: Otolaryngology-Head and Neck Surgery

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities